IRONWOOD PHARMS INC
PharmaIRONWOOD PHARMS INC is a pharmaceutical company with 2 FDA-approved products.
IRONWOOD PHARMS INC at a Glance
- Strong track record with 80% execution quality across 20 trials
- Fast trial execution (14 months median completion)
IRONWOOD PHARMS INC's Key Drugs
IRONWOOD PHARMS INC's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).
IRONWOOD PHARMS INC News
All IRONWOOD PHARMS INC news →- Nov 5, 2026 EarningsIronwood Pharmaceuticals Raises Full-Year 2026 Financial Guidance Driven by Continued LINZESS U.S. Net Sales Growth and Strong Third Quarter Financial Performance ↗
- Oct 16, 2026 CorporateIronwood Pharmaceuticals Appoints Tammi Gaskins as Chief Executive Officer – Tom McCourt to Retire from CEO Post After 17 Years at Ironwood and Four Decades of Distinguished Industry Leadership Bringing Transformational Medicines to Patients – ↗
IRONWOOD PHARMS INC's Recent FDA Approvals
New NDA/BLA approvals for IRONWOOD PHARMS INC over the last two years — novel drugs only, excluding generics and label supplements.
IRONWOOD PHARMS INC's Therapeutic Areas
Disease areas where IRONWOOD PHARMS INC has approved drugs and an active pipeline. Weighted by commercial stage — approved drugs count most, then late-stage trials.
IRONWOOD PHARMS INC Pipeline Snapshot
Active clinical trials for IRONWOOD PHARMS INC across all therapeutic areas, from ClinicalTrials.gov.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • Top drug revenue breakdown
- • Drug-level revenue analysis
Trial Catalysts
- • Active trial monitoring
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Execution Intelligence
- • Phase 3: 6/7 completed
- • Speed: 14 months avg
Revenue forecasts • Trial milestones • Patent risk modeling
How We Calculate These Metrics
Execution Quality Score
Measures trial completion rates weighted by phase importance. Phase 3 trials count 4x more than Phase 1 because late-stage completion is harder and more valuable.
What counts as "completed": A trial that reached its planned endpoint and reported results. Trials that were terminated early, withdrawn, or suspended are not counted as completed—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Excellent (80%+): Top-tier execution, most trials reach planned endpoints
- Good (60-79%): Strong execution with occasional early terminations
- Fair (40-59%): Average execution, notable rate of terminated/withdrawn trials
- Needs Improvement (under 40%): High termination rates, execution challenges